ArticleBMC oral health2026
Olanzapine-related oral health impairments: a scoping review and construction of a management framework.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOlanzapine is a commonly used second-generation antipsychotic. However, evidence on its oral health effects remains scattered, and clinical awareness is limited.
objectiveThis review systematically identifies the spectrum and epidemiological characteristics of olanzapine-related oral health impairments. It also proposes a framework for their pathogenesis, outlines existing management strategies, and clarifies evidence gaps.
methodsWe followed the JBI scoping review methodology and PRISMA-ScR guidelines. We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from database inception to December 31, 2025. Original studies and reviews focusing on olanzapine and oral health outcomes were included. Data were extracted using standardized tables and synthesized through thematic induction, evidence mapping, and gap analysis.
resultsA total of 18 studies meeting the inclusion criteria were finally included. A spectrum of oral impairments was identified. Reported prevalences included xerostomia (30%-60%), moderate-to-severe periodontitis (35.9%-60%), and oral ulcerations (16.19 per 1000 person-years). The DMFT (Decayed, Missing, Filled Teeth) index for dental caries ranged from 13.5 to 28.6. Oral bacterial-fungal dual dysbiosis was prevalent, and the risk of tongue movement abnormalities was increased (reporting odds ratio [ROR] = 6.7). This study proposed a "quadruple pathway synergistic amplification" model, which encompasses anticholinergic effects, metabolic disorders, microbial dysbiosis, and central neuro-behavioral abnormalities. The model suggests a potential interplay among drug effects, microbiota, metabolism, and inflammation. Current management is dominated by oral health education, with a lack of multidisciplinary collaboration; 70.6% of study outcome measures were non-standardized, with obvious evidence gaps.
conclusionOlanzapine-related oral health impairments appear common and potentially substantial, which may have potential clinical relevance. The stepwise "assessment-prevention-intervention-collaboration" management framework proposed in this study may provide a preliminary theoretical basis for future clinical hypothesis testing. These findings are hypothesis-generating and require validation in prospective cohorts and trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.